Skin Permeability and Pharmacokinetics of Diclofenac Epolamine Administered by Dermal Patch in Yorkshire-Landrace Pigs

Overview

Journal J Pain Res

Publisher Dove Medical Press

Date 2012 Nov 21

PMID 23166444

Citations 3

Authors

Susanna Tse

Kendall D Powell

Stephen J Maclennan

Allan R Moorman

Craig Paterson

Rosonald R Bell

Affiliations

Soon will be listed here.

Abstract

Purpose: This study compared the pharmacokinetic profile, and systemic and local absorption of diclofenac, following dermal patch application and oral administration in Yorkshire-Landrace pigs.

Patients And Methods: Twelve anesthetized, female, Yorkshire-Landrace pigs were randomized to receive either the dermal patch (FLECTOR(®) patch, 10 × 14 cm; Alpharma Pharmaceuticals, a subsidiary of Pfizer Inc, New York, NY) or 50 mg oral diclofenac (Voltaren(®); Novartis, East Hanover, NJ). Tissue (skin area of 2 × 2 cm and underlying muscles approximately 2-3 cm in depth) and blood (10 mL) samples were collected at timed intervals up to 11.5 hours after initial patch application or oral administration. The concentrations of diclofenac in plasma, skin, and muscle samples were analyzed using validated ultra performance liquid chromatography tandem mass spectrometric methods.

Results: Peak systemic exposure of diclofenac was very low by dermal application compared with oral administration (maximum concentration [C(max)] values of 3.5 vs 9640 ng/mL, respectively). Absorption of diclofenac into underlying muscles beneath the dermal patch was sustained, and followed apparently zero-order kinetics, with the skin serving as a depot with elevated concentrations of diclofenac. Concentrations of diclofenac in muscles beneath the patch application site were similar to corresponding tissues after oral administration (C(max) values of 879 and 1160 ng/mL, respectively). In contrast to the wide tissue distribution of diclofenac after oral administration, dermal patch application resulted in high concentrations of diclofenac only on the treated skin and immediate tissue underneath the patch. Low concentrations of diclofenac were observed in the skin and muscles collected from untreated areas contralateral to the site of dermal patch application.

Conclusion: Dermal patch application resulted in low systemic absorption and high tissue penetration of diclofenac compared with oral administration.

Citing Articles

Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits.

Mochizuki T, Hata T, Mori N, Yamazaki T, Noto T, Mano H Jpn J Ophthalmol. 2024; 68(5):594-602.

PMID: 38795193 PMC: 11420250. DOI: 10.1007/s10384-024-01070-6.

Efficacy and Safety of Lidocam Topical Gel (4% Lidocaine-0.3% Meloxicam) for Pain and Inflammation Management during Castration and Tail Docking in Piglets.

Nagel D, Ralston B, Hanson A, Burwash L, Matheson-Bird H, Olson B Animals (Basel). 2024; 14(6).

PMID: 38540028 PMC: 10967310. DOI: 10.3390/ani14060930.

Visualization of Epidermal Reservoir Formation from Topical Diclofenac Gels by Raman Spectroscopy.

Zhang Q, Flach C, Mendelsohn R, Page L, Whitson S, Boncheva Bettex M J Pain Res. 2020; 13:1621-1627.

PMID: 32753939 PMC: 7342390. DOI: 10.2147/JPR.S253069.

References

Petersen B, Rovati S . Diclofenac epolamine (Flector) patch: evidence for topical activity. Clin Drug Investig. 2008; 29(1):1-9. DOI: 10.2165/0044011-200929010-00001. View

Banning M . Topical diclofenac: clinical effectiveness and current uses in osteoarthritis of the knee and soft tissue injuries. Expert Opin Pharmacother. 2008; 9(16):2921-9. DOI: 10.1517/14656566.9.16.2921. View

Shah V, Midha K, Findlay J, HILL H, Hulse J, McGilveray I . Bioanalytical method validation--a revisit with a decade of progress. Pharm Res. 2001; 17(12):1551-7. DOI: 10.1023/a:1007669411738. View

Stanos S . Topical agents for the management of musculoskeletal pain. J Pain Symptom Manage. 2007; 33(3):342-55. DOI: 10.1016/j.jpainsymman.2006.11.005. View

Lionberger D, Joussellin E, Lanzarotti A, Yanchick J, Magelli M . Diclofenac epolamine topical patch relieves pain associated with ankle sprain. J Pain Res. 2011; 4:47-53. PMC: 3085263. DOI: 10.2147/JPR.S15380. View

Bansal S, DeStefano A . Key elements of bioanalytical method validation for small molecules. AAPS J. 2007; 9(1):E109-14. PMC: 2751299. DOI: 10.1208/aapsj0901011. View

Rainsford K, Kean W, Ehrlich G . Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine. Curr Med Res Opin. 2008; 24(10):2967-92. DOI: 10.1185/03007990802381364. View

Heyneman C, Wall G . Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs. 2000; 60(3):555-74. DOI: 10.2165/00003495-200060030-00004. View

Bode G, Clausing P, Gervais F, Loegsted J, Luft J, Nogues V . The utility of the minipig as an animal model in regulatory toxicology. J Pharmacol Toxicol Methods. 2010; 62(3):196-220. DOI: 10.1016/j.vascn.2010.05.009. View

10.

Jenoure P, Segesser B, Luhti U, Gremion G . A trial with diclofenac HEP plaster as topical treatment in minor sport injuries. Drugs Exp Clin Res. 1993; 19(3):125-31. View

11.

Lionberger D, Brennan M . Topical nonsteroidal anti-inflammatory drugs for the treatment of pain due to soft tissue injury: diclofenac epolamine topical patch. J Pain Res. 2011; 3:223-33. PMC: 3004639. DOI: 10.2147/JPR.S13238. View

12.

Fini A, Fazio G, Gonzalez-Rodriguez M, Cavallari C, Passerini N, Rodriguez L . Formation of ion-pairs in aqueous solutions of diclofenac salts. Int J Pharm. 1999; 187(2):163-73. DOI: 10.1016/s0378-5173(99)00180-5. View

13.

Qvist M, Hoeck U, Kreilgaard B, Madsen F, Frokjaer S . Evaluation of Göttingen minipig skin for transdermal in vitro permeation studies. Eur J Pharm Sci. 2000; 11(1):59-68. DOI: 10.1016/s0928-0987(00)00091-9. View

14.

Viswanathan C, Bansal S, Booth B, DeStefano A, Rose M, Sailstad J . Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007; 24(10):1962-73. DOI: 10.1007/s11095-007-9291-7. View

15.

Gschwend M, Martin W, Arnold P, Verdun M, Cambon N, Frentzel A . Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation. Arzneimittelforschung. 2005; 55(7):403-13. DOI: 10.1055/s-0031-1296879. View

16.

Singh P, Roberts M . Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther. 1994; 268(1):144-51. View

17.

Bookman A, Williams K, Shainhouse J . Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ. 2004; 171(4):333-8. PMC: 509045. DOI: 10.1503/cmaj.1031793. View

18.

Galer B, ROWBOTHAM M, Perander J, Devers A, Friedman E . Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manage. 2000; 19(4):287-94. DOI: 10.1016/s0885-3924(00)00125-1. View

19.

Oberle R, Das H, Wong S, Chan K, Sawchuk R . Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. Pharm Res. 1994; 11(5):698-703. DOI: 10.1023/a:1018976212986. View

20.

McCarberg B, Argoff C . Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury. Int J Clin Pract. 2010; 64(11):1546-1553. PMC: 2984542. DOI: 10.1111/j.1742-1241.2010.02474.x. View